Fig. 2

Vγ9Vδ2 T cell therapy exhibited different anti-tumor activities on patient-derived tumor cell clusters (PTCs) A GBM patients (n = 26) were categorized into two groups according to the antitumor effects of Vγ9Vδ2 T cells on matched PTCs by co-culture killing assay: stronger anti-tumor effect (SAT; n = 6) and weaker anti-tumor effect (WAT; n = 20) groups B–E Immunohistochemical (IHC) staining was performed to detect BTN2A1 B, C and BTN3A1 D, E expression in tumor tissue samples from patients in the SAT B, D and WAT C, E groups. F, G IHC scores were calculated. H RNA sequencing was performed on glioma tissue samples from patients. A heatmap of differentially expressed genes (DEGs; |fold change|> 2 and adjusted P-value < 0.05) in patients with SAT versus those with WAT is shown. I A volcano plot of the DEGs is displayed. J KEGG analysis of the DEGs was conducted. The top 14 enriched pathways are shown